Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis
Hansa Biopharma AB (Nasdaq Stockholm: HNSA) has announced the departure of Matthew Shaulis, Chief Commercial Officer and US President, effective late September 2024. The Commercial Leadership team will now report directly to Søren Tulstrup, President and CEO, while a search for a new CCO and US President is underway.
Shaulis expressed pride in the company's progress and its commitment to developing transformative products for patients with rare immunological diseases. Tulstrup acknowledged Shaulis's significant contributions, including commercialization efforts in Europe, acceleration of the ConfIdeS US pivotal study, and initiation of US launch planning.
Hansa Biopharma AB (Nasdaq Stoccolma: HNSA) ha annunciato il congedo di Matthew Shaulis, Chief Commercial Officer e Presidente degli Stati Uniti, a partire dalla fine di settembre 2024. Il team di Leadership Commerciale riporterà ora direttamente a Søren Tulstrup, Presidente e CEO, mentre è in corso la ricerca di un nuovo CCO e Presidente degli Stati Uniti.
Shaulis ha espresso orgoglio per i progressi dell'azienda e il suo impegno nello sviluppo di prodotti trasformativi per i pazienti affetti da malattie immunologiche rare. Tulstrup ha riconosciuto i significativi contributi di Shaulis, tra cui gli sforzi di commercializzazione in Europa, l'accelerazione dello studio pilota ConfIdeS negli Stati Uniti e l'avvio della pianificazione per il lancio negli Stati Uniti.
Hansa Biopharma AB (Nasdaq Estocolmo: HNSA) ha anunciado la salida de Matthew Shaulis, Director Comercial y Presidente de EE. UU., a partir de finales de septiembre de 2024. El equipo de Liderazgo Comercial ahora reportará directamente a Søren Tulstrup, Presidente y CEO, mientras se lleva a cabo la búsqueda de un nuevo CCO y Presidente de EE. UU.
Shaulis expresó su orgullo por el progreso de la empresa y su compromiso con el desarrollo de productos transformadores para pacientes con enfermedades inmunológicas raras. Tulstrup reconoció las significativas contribuciones de Shaulis, incluidos los esfuerzos de comercialización en Europa, la aceleración del estudio pivotal ConfIdeS en EE. UU. y la iniciación de la planificación del lanzamiento en EE. UU.
한사 바이오파마 AB (나스닥 스톡홀름: HNSA)는 매튜 샤울리스 최고 상업 책임자 겸 미국 대통령의 퇴직을 2024년 9월 말부터 발표했습니다. 상업 리더십 팀은 이제 소렌 튤스트럽 사장 겸 CEO에게 직접 보고하며, 새로운 CCO와 미국 대통령을 찾고 있습니다.
샤울리스는 회사의 발전과 희귀 면역 질환 환자를 위한 혁신적인 제품 개발에 대한 헌신에 자부심을 느낀다고 밝혔습니다. 튤스트럽은 유럽에서의 상업화 노력, 미국의 ConfIdeS 주요 연구 가속화, 미국 출시 계획 시작 등 샤울리스의 중요한 기여를 인정했습니다.
Hansa Biopharma AB (Nasdaq Stockholm: HNSA) a annoncé le départ de Matthew Shaulis, Directeur Commercial et Président des États-Unis, effectif fin septembre 2024. L'équipe de direction commerciale reportera désormais directement à Søren Tulstrup, Président et CEO, tandis qu'une recherche pour un nouveau CCO et Président des États-Unis est en cours.
Shaulis a exprimé sa fierté quant aux progrès de l'entreprise et à son engagement à développer des produits transformateurs pour les patients atteints de maladies immunologiques rares. Tulstrup a reconnu les contributions significatives de Shaulis, y compris les efforts de commercialisation en Europe, l'accélération de l'étude ConfIdeS aux États-Unis et le lancement de la planification du lancement aux États-Unis.
Hansa Biopharma AB (Nasdaq Stockholm: HNSA) hat den Rücktritt von Matthew Shaulis, Chief Commercial Officer und Präsident der USA, zum Ende September 2024 bekannt gegeben. Das Commercial Leadership Team wird nun direkt an Søren Tulstrup, Präsident und CEO, berichten, während die Suche nach einem neuen CCO und Präsidenten der USA im Gange ist.
Shaulis äußerte seinen Stolz über die Fortschritte des Unternehmens und dessen Engagement, transformative Produkte für Patienten mit seltenen immunologischen Erkrankungen zu entwickeln. Tulstrup würdigte Shaulis' bedeutende Beiträge, darunter die Kommerzialisierungsbemühungen in Europa, die Beschleunigung der US-Studie ConfIdeS und die Einleitung der Planung für den US-Start.
- Smooth transition with Commercial Leadership team reporting directly to CEO
- Ongoing search for new CCO and US President indicates proactive management
- Departure of key executive (CCO and US President) may disrupt commercial operations
- Potential loss of expertise and leadership in US market expansion efforts
Matthew Shaulis, CCO and US President, Hansa Biopharma said, "Joining Hansa was a key moment for my career and while the decision to leave was hard, especially given the company's solid progress, I know that the company will continue to advance innovative science, deliver on its commitment to develop and launch transformative new products, and help patients with rare immunological diseases. I'm proud of the work we have done together at Hansa."
Søren Tulstrup, President and CEO, Hansa Biopharma remarked, "Matt has been a fantastic addition to the Hansa executive team and has made significant contributions across the organization over the past years. I want to thank Matt for his commitment and dedication to advancing key priorities including commercialization efforts in
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com
Stephanie Kenney, VP Global Corporate Affairs
media@hansabiopharma.com
Notes to editors
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa Biopharma has a rich and expanding research and development program based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
https://mb.cision.com/Public/1219/4028110/bc9b46375205ee0e.pdf | 20240822 Shaulis Departure en |
View original content:https://www.prnewswire.com/news-releases/hansa-biopharma-announces-departure-of-chief-commercial-officer-matthew-shaulis-302229646.html
SOURCE Hansa Biopharma AB
FAQ
When is Matthew Shaulis leaving Hansa Biopharma (HNSA)?
Who will the Commercial Leadership team report to after Shaulis's departure from Hansa Biopharma (HNSA)?
What key contributions did Matthew Shaulis make during his tenure at Hansa Biopharma (HNSA)?
Is Hansa Biopharma (HNSA) seeking a replacement for Matthew Shaulis?
